WuXi Biologics (Cayman) Performance dei guadagni passati

Il passato criteri di controllo 3/6

WuXi Biologics (Cayman) ha registrato una crescita degli utili a un tasso medio annuo di 41.4%, mentre il settore Life Sciences ha registrato utili in crescita a un tasso medio annuo di 15.3%. I ricavi sono stati in crescita a un tasso medio annuo di 40.8%. Il ritorno sul capitale proprio di WuXi Biologics (Cayman) è 10.9% e ha margini netti di 25.1%.

Informazioni chiave

41.4%

Tasso di crescita degli utili

39.1%

Tasso di crescita dell'EPS

Life Sciences Crescita del settore	12.9%
Tasso di crescita dei ricavi	40.8%
Rendimento del capitale proprio	10.9%
Margine netto	25.1%
Prossimo aggiornamento sui guadagni	26 Mar 2024

Aggiornamenti sulle prestazioni recenti

Recent updates

Ripartizione dei ricavi e delle spese

Come WuXi Biologics (Cayman) guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

BMV:2269 N Ricavi, spese e utili (CNY Millions )
Data	Ricavi	Guadagni	Spese G+A	Spese di R&S
30 Jun 23	16,554	4,152	1,956	753
31 Mar 23	15,911	4,286	1,824	718
31 Dec 22	15,269	4,420	1,693	683
30 Sep 22	14,179	4,251	1,472	670
30 Jun 22	13,090	4,081	1,251	657
31 Mar 22	11,690	3,735	1,192	579
31 Dec 21	10,290	3,388	1,133	502
30 Sep 21	9,183	3,092	1,043	398
30 Jun 21	8,075	2,795	952	295
31 Mar 21	6,844	2,242	837	299
31 Dec 20	5,612	1,689	722	304
30 Sep 20	4,967	1,494	648	289
30 Jun 20	4,321	1,300	574	275
31 Mar 20	4,152	1,157	512	267
31 Dec 19	3,984	1,014	451	260
30 Sep 19	3,535	922	427	241
30 Jun 19	3,087	831	404	222
31 Mar 19	2,811	731	365	196
31 Dec 18	2,534	631	326	169
30 Sep 18	2,277	520	270	132
30 Jun 18	2,019	410	214	94
31 Mar 18	1,819	331	195	84
31 Dec 17	1,619	253	175	74
30 Sep 17	1,429	177	155	66
30 Jun 17	1,233	149	128	60
31 Mar 17	1,111	145	119	56
31 Dec 16	989	141	110	53
30 Sep 16	889	171	101	61
31 Dec 15	557	45	86	40
31 Dec 14	332	42	48	35

Guadagni di qualità: 2269 N ha guadagni di alta qualità.

Margine di profitto in crescita: Gli attuali margini di profitto netti di 2269 N (25.1%) sono inferiori rispetto allo scorso anno (31.2%).

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: Gli utili di 2269 N sono cresciuti in modo significativo del 41.4% all'anno negli ultimi 5 anni.

Accelerare la crescita: La crescita degli utili di 2269 N nell'ultimo anno ( 1.7% ) è inferiore alla media quinquennale ( 41.4% all'anno).

Guadagni vs Settore: La crescita degli utili 2269 N nell'ultimo anno ( 1.7% ) ha superato la percentuale del settore Life Sciences -3.9%.

WuXi Biologics (Cayman) Performance dei guadagni passati

Il passato criteri di controllo 3/6

Informazioni chiave

Aggiornamenti sulle prestazioni recenti

WuXi Biologics (Cayman) Inc. to Report First Half, 2024 Results on Aug 21, 2024

WuXi Biologics (Cayman) Inc. to Report Q4, 2023 Results on Mar 26, 2024

WuXi Biologics (Cayman) Inc. to Report First Half, 2023 Results on Aug 23, 2023

WuXi Biologics (Cayman) Inc. to Report Fiscal Year 2022 Results on Mar 22, 2023

First half 2022 earnings released: EPS: CN¥0.61 (vs CN¥0.44 in 1H 2021)

First half 2022 earnings released: EPS: CN¥0.61 (vs CN¥0.44 in 1H 2021)

Recent updates

WuXi Biologics (Cayman) Inc. (SEHK:2269) completed the acquisition of remaining 30% stake in WuXi Vaccines (Cayman) Inc. from Shanghai Hile Bio-Technology Co., Ltd. (SHSE:603718).

WuXi Reportedly Explores Sale of Pharma Units as US Restrictions Loom

WuXi Biologics Successfully Completes First Scale-Up of High-Productivity Bioprocessing Platform WuXiUI in 2,000L GMP Manufacturing

WuXi Biologics (Cayman) Inc. to Report First Half, 2024 Results on Aug 21, 2024

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 19, 2024

WuXi Biologics (Cayman) Inc.(SEHK:2269) dropped from S&P Global 1200

WuXi Biologics (Cayman) Inc.(SEHK:2269) dropped from S&P International 700

WuXi Biologics (Cayman) Inc. to Report Q4, 2023 Results on Mar 26, 2024

WuXi Biologics Successfully Completes First 1,6000L Manufacturing Run in Ireland

WuXi Biologics Launches WuXia ADCC PLUS™ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect

WuXi Biologics Receives U.S. Patent for Proprietary Bispecific Antibody Technology Platform WuXiBody™

WuXi Biologics (Cayman) Inc. Announces Executive Changes, Effective March 31, 2024

Less than half of directors are independent

WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 424,841,177 shares, representing 10% of its issued share capital, under the authorization approved on June 27, 2023.

Wuxi Biologics Successfully Implements Fully Integrated Continuous Process with Breakthrough Productivity of 6 g/L/Day At Pilot Scale

WuXi Biologics Launches New High-Productivity Bioprocessing Platform WuXiUI™ for Cost-Effective Commercial Manufacturing and Desirable Product Quality

Wuxi Biologics (Cayman) Inc. Announces Executive Changes

WuXi Biologics (Cayman) Inc. to Report First Half, 2023 Results on Aug 23, 2023

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 15, 2023

WuXi Biologics (Cayman) Inc. Announces Demise of Ning Zhao, Non-Executive Director, Member of Remuneration Committee and Member of Environmental, Social and Governance Committee

WuXi Biologics (Cayman) Inc. Announces Board and Board Committee Changes

Investor sentiment deteriorates as stock falls 26%

Less than half of directors are independent

WuXi Biologics (Cayman) Inc. to Report Fiscal Year 2022 Results on Mar 22, 2023

Less than half of directors are independent

WuXi Biologics (Cayman) Inc. Announces Demise of Teh-Ming Walter Kwauk, Independent Non-Executive Director, the Chairman of the Audit Committee of the Company and A Member of the Nomination Committee of the Company

Wuxi Biologics (Cayman) Inc. Announces Appointments to Strategy Committee

WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 425,926,547 shares, representing 10% of its issued share capital, under the authorization approved on June 10, 2022.

First half 2022 earnings released: EPS: CN¥0.61 (vs CN¥0.44 in 1H 2021)

WuXi Biologics (Cayman) Inc. Receives Regulatory Approvals for Drug Substance and Drug Product Facilities from U.S. FDA and EMA

Investor sentiment deteriorated over the past week

Less than half of directors are independent

First half 2022 earnings released: EPS: CN¥0.61 (vs CN¥0.44 in 1H 2021)

Less than half of directors are independent

WuXi Biologics (Cayman) Inc. Appoints Weichang Zhou as Member of the Strategy Committee

WuXi Biologics (Cayman) Inc. Provides Earnings Guidance for the Six Months Ended June 30, 2022

Less than half of directors are independent

CEO & Executive Director recently sold Mex$45m worth of stock

Investor sentiment improved over the past week

Less than half of directors are independent

Less than half of directors are independent

Wuxi Biologics (Cayman) Inc. Provides Unaudited Consolidated Earnings Guidance for the Ended December 31, 2021

WuXi Biologics Announces Completion of GMP Production At 24,000L Line of Its Drug Substance Facility MFG5

CEO & Executive Director recently bought Mex$102m worth of stock

Less than half of directors are independent

WuXi Biologics (Cayman) Inc. Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended June 30, 2021

CEO & Executive Director recently sold Mex$88m worth of stock

WuXi Biologics (Cayman) Inc. (SEHK:2269) completed the acquisition of Biologics manufacturing facilities in Hangzhou of Pfizer Investment Co. Ltd.

Full year 2020 earnings released: EPS CN¥0.43 (vs CN¥0.27 in FY 2019)

Insider recently bought Mex$9.2m worth of stock

Full year 2020 earnings released: EPS CN¥0.43 (vs CN¥0.27 in FY 2019)

WuXi Biologics (Cayman) Inc. (SEHK:2269) agreed to acquire a 90% stake in CMAB Biopharma Inc. from CBC Group.

WuXi Biologics (Cayman) Inc. (SEHK:2269) entered into an equity agreement to acquire Biologics manufacturing facilities in Hangzhou of Pfizer Investment Co. Ltd.

Exelixis, Inc. Enters into License Agreement with WuXi Biologics to Support Further Expansion of its Growing Oncology Biologics Pipeline

Wuxi Biologics (Cayman) Inc. Receives Remote Pre-Approval Inspection by European Medicines Agency on MFG4 Facility

WuXi Biologics (Cayman) Inc. to Report Fiscal Year 2020 Results on Mar 23, 2021

Antengene Corporation Limited Announces Collaboration with WuXi Biologics and WuXi STA to Advance Antibody-Drug Conjugate Candidate into Clinical-stage

Executive VP recently sold Mex$275m worth of stock

Oxford BioTherapeutics Ltd Designates Second Bispecific Antibody Program Leveraging Wuxi Biologics’ Wuxibody® Platform

Oxford BioTherapeutics Designates Second Bispecific Antibody Program Leveraging WuXi Biologics’ WuXiBody® Platform

WuXi Biologics Receives GMP Certification from Brazil's ANVISA

Ripartizione dei ricavi e delle spese

Storia dei guadagni e delle entrate

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Rendimento del capitale proprio

Rendimento delle attività

Rendimento del capitale investito

Scoprire le aziende con forti performance passate